AKT1 and diabetes mellitus: Phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT) inhibitor induced hyperglycemia is particularly likely to happen in patients with baseline diabetes, pre‐diabetes, or elevated body mass index.